JP2024511389A - キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法 - Google Patents

キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法 Download PDF

Info

Publication number
JP2024511389A
JP2024511389A JP2023557142A JP2023557142A JP2024511389A JP 2024511389 A JP2024511389 A JP 2024511389A JP 2023557142 A JP2023557142 A JP 2023557142A JP 2023557142 A JP2023557142 A JP 2023557142A JP 2024511389 A JP2024511389 A JP 2024511389A
Authority
JP
Japan
Prior art keywords
group
compound
compounds
cancer
ret
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511389A5 (https=
Inventor
チェン，ヂョンフイ
ユアン，シャオシー
レイ，ドンメイ
ハン，ルンフェン
ハン，シャオジュン
ティエン，チアン
ソン，ホンメイ
ワン，ジンイー
Original Assignee
スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド filed Critical スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド
Publication of JP2024511389A publication Critical patent/JP2024511389A/ja
Publication of JP2024511389A5 publication Critical patent/JP2024511389A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023557142A 2021-03-24 2022-03-21 キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法 Pending JP2024511389A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110316525 2021-03-24
CN202110316525.6 2021-03-24
CN2022074619 2022-01-28
CN202210109766 2022-01-28
CNPCT/CN2022/074619 2022-01-28
CN202210109766.8 2022-01-28
PCT/CN2022/081890 WO2022199503A1 (zh) 2021-03-24 2022-03-21 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Publications (2)

Publication Number Publication Date
JP2024511389A true JP2024511389A (ja) 2024-03-13
JP2024511389A5 JP2024511389A5 (https=) 2025-03-25

Family

ID=83396096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557142A Pending JP2024511389A (ja) 2021-03-24 2022-03-21 キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法

Country Status (7)

Country Link
US (1) US20250268897A1 (https=)
EP (1) EP4316490A4 (https=)
JP (1) JP2024511389A (https=)
KR (1) KR20230159367A (https=)
CN (1) CN116801882A (https=)
AU (1) AU2022242476A1 (https=)
WO (1) WO2022199503A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022022398A1 (zh) * 2020-07-28 2022-02-03 四川科伦博泰生物医药股份有限公司 一种嘧啶类化合物的盐和晶型及其制备方法
CN120897743A (zh) 2023-05-19 2025-11-04 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与ret基因改变相关疾病的用途和方法
WO2026017002A1 (zh) * 2024-07-16 2026-01-22 四川科伦博泰生物医药股份有限公司 以杂环化合物为活性成分的药物组合物、其制备方法及用途
GB202410599D0 (en) 2024-07-19 2024-09-04 Ellipses Pharma Ltd Therapeutics useful synergistic combinations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075108A1 (en) * 2017-10-10 2019-04-18 Metcalf Andrew T CRYSTALLINE FORMS
WO2019143977A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2020168939A1 (zh) * 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 杂环化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145391B2 (en) * 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
US10227329B2 (en) * 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
EA202193049A1 (ru) * 2019-05-21 2022-02-14 Вороной Инк. N-содержащее производное гетероарила и фармацевтическая композиция, содержащая его в качестве активного ингредиента для предупреждения или лечения рака
JP7732668B2 (ja) * 2019-08-05 2025-09-02 北京志健金瑞生物医▲薬▼科技有限公司 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075108A1 (en) * 2017-10-10 2019-04-18 Metcalf Andrew T CRYSTALLINE FORMS
WO2019143977A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2020168939A1 (zh) * 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 杂环化合物、包含其的药物组合物及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCERS, vol. 13, no. 1091, JPN6026007038, 4 March 2021 (2021-03-04), pages 1 - 23, ISSN: 0005802333 *
JOURNAL OF THORACIC ONCOLOGY, vol. 15, no. 4, JPN6026007039, 2020, pages 541 - 549, ISSN: 0005802334 *

Also Published As

Publication number Publication date
US20250268897A1 (en) 2025-08-28
EP4316490A4 (en) 2025-03-05
EP4316490A1 (en) 2024-02-07
KR20230159367A (ko) 2023-11-21
WO2022199503A1 (zh) 2022-09-29
CN116801882A (zh) 2023-09-22
AU2022242476A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
JP7487421B2 (ja) Ｐｒｍｔ５阻害剤
JP6876833B2 (ja) Ｆｇｆｒ阻害剤およびその使用
JP6726677B2 (ja) 抗がん剤としての置換２−ｈ−ピラゾール誘導体
JP2022523274A (ja) Ｊａｋ阻害剤化合物及びその使用
JP2024511389A (ja) キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法
EP2763533B1 (en) Triazolyl pde10 inhibitors
JP7821259B2 (ja) 複素環化合物、これを含む薬物組成物、その製造方法および使用
EP4713096A1 (en) Cdk inhibitor compounds
JP6200520B2 (ja) 置換２−アミノピリジンプロテインキナーゼ阻害剤
AU2005289644A1 (en) Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
EP3071571A1 (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors
WO2022155419A1 (en) Indazoles and azaindazoles as lrrk2 inhibitors
TW202140446A (zh) 喹啉基膦氧化合物及其組合物和用途
RU2828045C2 (ru) Гетероциклическое соединение, фармацевтическая композиция, содержащая его, способ его получения и его применение
EP4556478A1 (en) Tgf-beta inhibitor compound and use thereof
CN117126140A (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
WO2025255294A1 (en) Pkc-theta inhibitors, compositions, and methods of use
US20260125346A1 (en) Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease
CN121914104A (zh) Cdk12抑制剂、包含其的药物组合物和用途
CN116761801A (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224